Condition: Recurrent or Metastatic Solid Tumors · Sponsor: Daiichi Sankyo
This dose escalation and dose expansion study was designed to assess the safety, tolerability, PK and efficacy of subcutaneous T-DXd in participants with metastatic solid tumors.
This description comes directly from the study's public registry record.
Contact for Trial Information · 908-992-6400 · CTRinfo_us@daiichisankyo.com
Always discuss trial participation with your own doctor first.
| Research Site | Newport Beach, California, United States | Recruiting |
| Research Site | Atlanta, Georgia, United States | Recruiting |
| Research Site | Las Vegas, Nevada, United States | Recruiting |
| Research Site | Charlotte, North Carolina, United States | Recruiting |
| Research Site | Maumee, Ohio, United States | Recruiting |
| Research Site | Nashville, Tennessee, United States | Recruiting |
| Research Site | Asa Sul, Brazil | Not Yet Recruiting |
| Research Site | Goiás, Brazil | Not Yet Recruiting |
| Research Site | Porto Alegre, Brazil | Not Yet Recruiting |
| Research Site | Santo André, Brazil | Not Yet Recruiting |
| Research Site | São Paulo, Brazil | Not Yet Recruiting |
| Research Site Saint | Herblain, France | Recruiting |
+ 19 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07015697